Anti-CLEC2D Antibodies for Blocking CLEC2D-CD161 Immune Escape
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The interaction between CLEC2D and CD161 leads to immune escape in diseases such as cancer, inhibiting NK cell functions and stimulating T cell proliferation, with downstream signaling poorly understood.
Innovation Solution
Development of antibodies or antigen-binding fragments that specifically bind to CLEC2D with varying degrees of sequence identity, targeting the interaction between CLEC2D and CD161 to disrupt their binding and modulate immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CLEC2D-CD161 interaction is allowed to occur, then immune escape is facilitated and NK cell functions are inhibited, but blocking this interaction requires specific antibody development which increases device complexity
Solution Approach 1:
The antibody is divided into functional segments: variable regions (VH and VL) that recognize and bind to CLEC2D, and constant regions that provide structural stability and effector functions. This segmentation allows the antibody to specifically target the CLEC2D-CD161 interaction interface while maintaining overall molecular stability, thereby blocking immune escape without requiring complete redesign of the entire immune system
Solution Approach 2:
The antibody acts as an intermediary molecule that binds to CLEC2D on tumor cells and prevents its interaction with CD161 on NK cells. This intermediary approach blocks the harmful CLEC2D-CD161 interaction without directly modifying NK cells or tumor cells, providing a controllable and reversible mechanism to restore immune function
2Measurement precision
If high sequence identity antibodies are developed to ensure specific binding, then binding precision improves, but manufacturing complexity increases
Solution Approach 1:
The antibody achieves high binding specificity through localized precision in the complementarity-determining regions (CDRs), particularly CDRH3 and CDRL3, which directly contact CLEC2D. The framework regions use more conserved sequences that are easier to manufacture. This local quality approach concentrates the specificity requirements in small regions while allowing greater flexibility in the rest of the molecule, balancing binding precision with manufacturing ease
Solution Approach 2:
The patent explores antibodies with varying sequence identities (90-100% identical to reference sequences) to optimize the balance between binding affinity and manufacturability. By adjusting amino acid substitutions in non-critical regions while maintaining critical binding residues, the patent identifies optimal sequences that achieve sufficient specificity without excessive manufacturing complexity
Data Source
AI summary
The present disclosure relates to novel anti-CLEC2D antibodies and related compositions and methods of use thereof These antibodies are used as therapeutics, and in prognostic and diagnostic applications in various cancers and other diseases.